Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib for Barrett's Esophagus (CBET)
NCT00005878Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2000
- Primary completion
- Sep 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Barrett's esophagus and esophageal cancer comparing Celecoxib with Placebo (2 arms). Primary endpoint: Safety and efficacy of celecoxib for regression of Barrett's dysplasia at 48 weeks. Started Jul 2000; status: completed.
02
Drugs
celecoxib
03
Conditions
Barrett's esophagusesophageal cancer
Beyond the preview
Go deeper on NCT00005878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005878.